VytronUS is a Sunnyvale, Calif.-based medical device company developing the Low-Intensity Collimated Ultrasound (LICU) Cardiac Mapping & Ablation System. The company is building an integrated imaging and ablation platform for cardiac electrophysiologists that harnesses ultrasound energy to create high-resolution interior heart images for procedure planning. The system allows physicians to draw a desired treatment pattern on the image at the workstation to guide ablation for atrial fibrillation and other arrhythmias. VytronUS raised $49m in Series C equity financing from Apple Tree Partners, NEA, BioStar Ventures and Windham Venture Partners. The company intends to use the funds for technology refinements and clinical trials of its LICU system. VytronUS is led by CEO John Pavlidis. VytronUS is a Sunnyvale, CA-based medical device company developing novel technologies for the treatment of cardiac arrhythmias. It has developed a catheter-based ablation platform employing Low-Intensity Collimated Ultrasound (LICU) that enables non-contact energy delivery and rapid, high-resolution imaging of cardiac anatomy. The company is developing an integrated imaging and ablation system for cardiac electrophysiologists intended to treat atrial fibrillation and other arrhythmias. VytronUS secured $31.6M in Series B financing led by Apple Tree Partners with participation from BioStar Ventures, Windham Venture Partners, a strategic investor, New Enterprise Associates and other existing investors. The funds will be used for development and validation of its proprietary LICU Cardiac Imaging and Ablation System and to support forthcoming clinical trials. As part of the financing, Apple Tree’s David McIntyre and Sami Hamade and BioStar’s Hank Kucheman will join the company’s board. Michael Pederson is CEO but will step down later this quarter to lead Abbott’s newly-formed electrophysiology business.

Total raised

$81M

Funding rounds

2

Latest round

Series C

Latest activity

Jul 2016